Global CRISPR Market 2025-2035

Description

List of Tables

CRISPR Market Size, Share & Trends Analysis Report by Application (Cell Line Engineering, CRISPR Plasmid, Gene Database/Gene Library, Genetic Engineering, Genetically Modified Organisms or Crops, Genome Editing, Human Stem Cells), and by End-User (Academic Institutes, Biotechnology Companies, Pharmaceuticals Companies, and Research and Development Institutes), Forecast Period (2025-2035)

Industry Overview

CRISPR market size, valued at $2,650 million in 2024, is projected to grow to $8,890 million by 2035, registering a CAGR of 11.6% during 2025-2035. The CRISPR market growth is driven by increasing government and private funding, as well as rising demand for CRISPR, coupled with advancements in technology. CRISPR has wide applications in genome engineering, RNA editing, Gene drive, Gene function, in vitro genetic depletion, biomedicine, disease models, and many more.

Market Dynamics

Rising Genetic Disorders are Increasing the Demand for CRISPR Technology

The demand for CRISPR is driven by increasing genetic disorders and rare diseases around the globe. According to the World Health Organization (WHO), a rare disease affects 1 in every 2,000 individuals in the general population. Recently, there have been more than 7,000 known rare diseases impacting over 300 million people globally. While 70% of these conditions begin in childhood. Additionally, there are limited resources for research and diagnosis, as well as insufficient investment and financial incentives for drug development in the area of rare diseases. As a result, more than 95% of rare diseases still lack effective treatment, which further supports the development of CRISPR-based therapies.

Limitations of CRISPR/Cas9 technology and future promise

CRISPR technology, along with innovations such as base editing and prime editing techniques, are facing traditional challenges, including off-target effects (gRNA may bind to non-target genomic sites, can initiate unintended mutations), host immune responses (as endogenous bacterial Cas9 proteins can trigger immune-mediated degradation in human cells), and ethical and regulatory challenges (with 70 countries having established clear policies against CRISPR). These limitations are increasing CRISPR's therapeutic potential and making it more accessible to researchers and clinicians globally. Additionally, the integration of artificial intelligence with CRISPR technology is further enhancing the precision and efficiency of gene editing.

Market Segmentation

Based on the application, the market is segmented into cell line engineering, CRISPR plasmid, gene database/gene library, genetic engineering, genetically modified organisms or crops, genome editing, and human stem cells.
Based on the end-user, the market is segmented into academic institutes, biotechnology companies, pharmaceutical companies, and research and development institutes.

Biomedical Application holds a Significant Share in the CRISPR Market

The major biomedical applications of the CRISPR technology include drug discovery, gene therapy, and diagnostics. The increase in clinical trials of gene therapy across the globe is one of the major factors driving market growth. CRISPR technology in drug discovery is used for developing more physiologically relevant models, such as cell line models that correlate with clinical settings. This improvement can lead to a reduction in the failure rates of drug candidates during the initial testing phases. For Instance, in August 2023, 90% of the soybean plants are genetically modified through molecular breeding techniques, specifically using CRISPR/Cas9 gene editing technology. This technology is applied to modify functional soybean genes, enabling regulation of traits such as oil content, flowering based on photoperiod, seed coat color, seed size, plant height, and nodulation.

For example, 90% of soybean plants are genetically modified through molecular breeding techniques, specifically using CRISPR/Cas9 gene editing technology. This technology is applied to modify functional soybean genes, enabling regulation of traits such as oil content, flowering based on photoperiod, seed coat color, seed size, plant height, and nodulation.

Regional Outlook

The global CRISPR market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Dominates the CRISPR Market

North America holds the largest market share of the global CRISPR market. The region continues to dominate the growing CRISPR ecosystem due to strong research infrastructure, favorable regulatory environments, large government investment, and major biotechnology and pharmaceutical companies. For instance, in 2019, the National Institutes of Health (NIH) awarded 24 new grants to researchers in the U.S. and Canada through the Somatic Cell Genome Editing (SCGE) program. These awards amount to approximately $89 million over four years, with these 24 new projects bringing the total number of supported projects to 45 and total funding to approximately $190 million over six years, pending available funds.

Market Players Outlook

The global CRISPR market is highly competitive with a significant number of global and regional vendors. Beam Therapeutics Inc., CRISPR Therapeutics AG, Editas Medicine, Inc., Genscript Biotech Corp., and Intellia Therapeutics Inc. Additionally, the strategic partnership between market players also contributes to market growth. For instance, in December 2017, CRISPR Therapeutics and Vertex Pharmaceuticals collaborated on the CTX00, which is the first CRISPR/Cas9-based treatment for B-thalassemia and sickle cell disease.

Recent Developments

In July 2025, Integrated DNA Technologies is set to revolutionize the field of translational gene editing with new additions to its end-to-end CRISPR portfolio. These enhanced CRISPR translational research solutions are designed to help researchers accelerate the development of CRISPR-based therapies for patients.
In May 2025, CRISPR Therapeutics and Sirius Therapeutics, a company focused on developing innovative small interfering RNA (siRNA) therapies, to create and commercialize siRNA therapies. The therapy identified as SRSD107 is a next-generation, long-acting siRNA designed to selectively inhibit Factor XI (FXI).
In December 2023, the US Food and Drug Administration approved two treatments, Casgevy and Lyfgenia. These are the first cell-based gene therapies approved for the treatment of sickle cell disease (SCD). Casgevy is the first FDA-approved therapy utilizing CRISPR/Cas9, a type of genome editing technology.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global CRISPR market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2028914

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global CRISPR Market Sales Analysis - Application | End-User ($ Million)
CRISPR Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key CRISPR Market Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For the Global CRISPR Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For the Global CRISPR Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For the Global CRISPR Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - CRISPR Market Revenue and Share by Manufacturers
CRISPR Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Beam Therapeutics Inc.
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. CRISPR Therapeutics AG
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Editas Medicine, Inc.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Genscript Biotech Corp.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Intellia Therapeutics Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global CRISPR Market Sales Analysis by Application ($ Million)

5.1. Cell Line Engineering
5.2. CRISPR Plasmid
5.3. Gene Database/Gene Library
5.4. Genetic Engineering
5.5. Genetically Modified Organisms Crops
5.6. Genome Editing
5.7. Human Stem Cells

6. Global CRISPR Market Sales Analysis by End-User ($ Million)

6.1. Academic Institutes
6.2. Biotechnology Companies
6.3. Pharmaceuticals Companies
6.4. Research and Development Institutes

7. Regional Analysis

7.1. North American CRISPR Market Sales Analysis - Application | End-User| Country ($ Million)
Macroeconomic Factors for North America
- 7.1.1. United States
- 7.1.2. Canada
7.2. European CRISPR Market Sales Analysis - Application | End-User | Country ($ Million)
Macroeconomic Factors for Europe
- 7.2.1. UK
- 7.2.2. Germany
- 7.2.3. Italy
- 7.2.4. Spain
- 7.2.5. France
- 7.2.6. Russia
- 7.2.7. Rest of Europe
7.3. Asia-Pacific CRISPR Market Sales Analysis - Application | End-User | Country ($ Million)
Macroeconomic Factors for Asia-Pacific
- 7.3.1. China
- 7.3.2. Japan
- 7.3.3. South Korea
- 7.3.4. India
- 7.3.5. Australia & New Zealand
- 7.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 7.3.7. Rest of Asia-Pacific
7.4. Rest of the World CRISPR Market Sales Analysis - Application | End-User | Country ($ Million)
Macroeconomic Factors for the Rest of the World
- 7.4.1. Latin America
- 7.4.2. Middle East and Africa

8. Company Profiles

8.1. AstraZeneca plc
- 8.1.1. Quick Facts
- 8.1.2. Company Overview
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategies
8.2. Applied StemCell, Inc.
- 8.2.1. Quick Facts
- 8.2.2. Company Overview
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategies
8.3. Bio-Rad Laboratories, Inc.
- 8.3.1. Quick Facts
- 8.3.2. Company Overview
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategies
8.4. Beam Therapeutics Inc.
- 8.4.1. Quick Facts
- 8.4.2. Company Overview
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategies
8.5. Caribou Bioscience Inc.
- 8.5.1. Quick Facts
- 8.5.2. Company Overview
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategies
8.6. Cellectics SA
- 8.6.1. Quick Facts
- 8.6.2. Company Overview
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategies
8.7. CRISPR Therapeutics AG
- 8.7.1. Quick Facts
- 8.7.2. Company Overview
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategies
8.8. Creative Biogene
- 8.8.1. Quick Facts
- 8.8.2. Company Overview
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategies
8.9. DH Life Sciences, LLC
- 8.9.1. Quick Facts
- 8.9.2. Company Overview
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategies
8.10. Editas Medicine, Inc.
- 8.10.1. Quick Facts
- 8.10.2. Company Overview
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategies
8.11. Genscript Biotech Corp.
- 8.11.1. Quick Facts
- 8.11.2. Company Overview
- 8.11.3. Product Portfolio
- 8.11.4. Business Strategies
8.12. GeneCopoeia, Inc.
- 8.12.1. Quick Facts
- 8.12.2. Company Overview
- 8.12.3. Product Portfolio
- 8.12.4. Business Strategies
8.13. Illumina, Inc.
- 8.13.1. Quick Facts
- 8.13.2. Company Overview
- 8.13.3. Product Portfolio
- 8.13.4. Business Strategies
8.14. Integrated DNA Technologies, Inc.
- 8.14.1. Quick Facts
- 8.14.2. Company Overview
- 8.14.3. Product Portfolio
- 8.14.4. Business Strategies
8.15. Intellia Therapeutics Inc.
- 8.15.1. Quick Facts
- 8.15.2. Company Overview
- 8.15.3. Product Portfolio
- 8.15.4. Business Strategies
8.16. Lonza Group Ltd.
- 8.16.1. Quick Facts
- 8.16.2. Company Overview
- 8.16.3. Product Portfolio
- 8.16.4. Business Strategies
8.17. Merck KGaA
- 8.17.1. Quick Facts
- 8.17.2. Company Overview
- 8.17.3. Product Portfolio
- 8.17.4. Business Strategies
8.18. Mammoth Biosciences, Inc.
- 8.18.1. Quick Facts
- 8.18.2. Company Overview
- 8.18.3. Product Portfolio
- 8.18.4. Business Strategies
8.19. New England Biolabs GmbH
- 8.19.1. Quick Facts
- 8.19.2. Company Overview
- 8.19.3. Product Portfolio
- 8.19.4. Business Strategies
8.20. Origene Technologies, Inc.
- 8.20.1. Quick Facts
- 8.20.2. Company Overview
- 8.20.3. Product Portfolio
- 8.20.4. Business Strategies
8.21. Precision Bioscience, Inc.
- 8.21.1. Quick Facts
- 8.21.2. Company Overview
- 8.21.3. Product Portfolio
- 8.21.4. Business Strategies
8.22. Revvity Discovery Ltd.
- 8.22.1. Quick Facts
- 8.22.2. Company Overview
- 8.22.3. Product Portfolio
- 8.22.4. Business Strategies
8.23. Synthego Holdings LLC
- 8.23.1. Quick Facts
- 8.23.2. Company Overview
- 8.23.3. Product Portfolio
- 8.23.4. Business Strategies
8.24. Thermo Fisher Scientific Inc.
- 8.24.1. Quick Facts
- 8.24.2. Company Overview
- 8.24.3. Product Portfolio
- 8.24.4. Business Strategies
8.25. ToolGen Inc.
- 8.25.1. Quick Facts
- 8.25.2. Company Overview
- 8.25.3. Product Portfolio
- 8.25.4. Business Strategies
8.26. Takara Bio Inc.
- 8.26.1. Quick Facts
- 8.26.2. Company Overview
- 8.26.3. Product Portfolio
- 8.26.4. Business Strategies